@FierceBiotech: Chutes & Ladders: Bristol-Myers' senior VP of global development retires. Story | Follow @FierceBiotech
@JohnCFierce: Merck KGaA says for the umpteenth time they're going to do some pharma deals. Loaded for bear. More | Follow @JohnCFierce
@DamianFierce: Today in PfAy-Z: Pfizer cozies up to U.K. researchers in 5-year rare disease pact. Article | Follow @DamianFierce
@EmilyMFierce: Antibiotic-resistant genes are almost everywhere. News | Follow @EmilyMFierce
> Pfizer's ($PFE) breakthrough-designated meningococcal B vaccine came through in a Phase II study, charting positive data the company plans to submit to the FDA by mid-year. News
> Lumena Pharmaceuticals has kicked off a Phase II study of its top drug prospect in children with progressive familial intrahepatic cholestasis, one of 7 trials the biotech is running as it prepares for a planned $75 million IPO. Item
> Akorn ($AKRX) has signed a deal to buy specialty pharma outfit VersaPharm for $440 million in cash. More
@FierceMedDev: Masimo hit with subpoena over patient-monitoring tech. More | Follow @FierceMedDev
@VarunSaxena2: House votes to make R&D tax credit permanent. What will Senate do? Seems to prefer 2 year extension. Story via WSJ (sub. req.) | Follow @VarunSaxena2
@MichaelGFierce: Double-locked virus needs two enzyme 'keys' to release drugs. Story via FierceDrugDelivery | Follow @MichaelGFierce
> Study finds common test of ICD patients to be unnecessary. More
> Counsyl raises $28M, launches BRCA test. Piece
Pharma News
@FiercePharma: Pfizer's move on AstraZeneca outrages pols on two continents. More | Follow @FiercePharma
@TracyStaton: Popular at FiercePharmaMarketing: Payers fret about the next drug doomsday: Pricey PCSK9 cholesterol meds. Story | Follow @TracyStaton
@EricPFierce: CEO says Teva will close at least 11 plants, 15% of its network, and 16 more are being evaluated. Article | Follow @EricPFierce
@CarlyHFierce: U.K.'s NICE throws Astellas a bone on Xtandi--or does it? Report | Follow @CarlyHFierce
> Actavis slaps struggling Vivus with generic threat. More
> Merck gets approval for Zontivity for reducing stroke and heart attack risks. Item
> Ranbaxy losses pile up as it awaits the healing powers of Sun. Article